Author: admin

Coaching for Causes: Empowering personal growth while giving back

14 certified coaches share their downtime to support 22 charitable initiatives, through a donation-based program

Santa Monica, CA – May 3, 2024 – Coaching for Causes, a charitable initiative founded by Professional Development and Career Coach Caroline Lenher in 2022, is gearing up for another year of giving back in the month of May. This initiative brings together Certified Professional Coaches who provide one-on-one coaching sessions while raising funds for local and global causes.

What sets Coaching for Causes apart is its dual commitment to personal growth and community support. Certified coaches from various disciplines volunteer their coaching hours, offering transformative sessions to individuals seeking personal or professional development. 

For the month of May, in exchange, participants make a minimum donation of $50 to one or more of the 22 causes supported by the initiative, ranging from health-related charities like the American Brain Tumor Association and Basser Center for BRCA to community-focused organizations like Big Brother’s Big Sisters and The Celebrate Life Foundation to global causes like Doctors Without Borders and World Central Kitchen. The causes are those closest to our participating coaches’ hearts.

The full list includes:

  • Alzheimer’s Association
  • American Brain Tumor Association
  • America’s Dinner Table
  • Basser Center for BRCA
  • Big Brothers Big Sisters of Greater Los Angeles
  • Boston Children’s Hospital
  • Doctors Without Borders
  • Fight Colorectal Cancer
  • Leukemia & Lymphoma Society
  • Mary’s Place
  • Ocean Conservancy
  • Parkinson’s Foundation
  • Project Street Vet
  • Runway to Hope
  • School on Wheels
  • Seeds of Peace
  • Southern Paws
  • Susan G Komen
  • Tanenbaum
  • The Celebrate Life Foundation
  • There with Care
  • World Central Kitchen

Since its inception, Coaching for Causes has experienced tremendous growth. What started with a collaboration of six coaches has expanded to include 14 dedicated professionals in 2024. With the launch of a dedicated website, the company aims to reach even more individuals and raise greater funds for the causes close to their hearts.

Caroline Lenher, the founder of Coaching for Causes, expresses her passion for the initiative, stating, “Giving coaching time in exchange for supporting impactful causes feels like the least we can do to support those in need of coaching support while making our communities and the world a better place.”

To participate in Coaching for Causes, individuals can visit the website and select a coach whose specialties align with their needs. After confirming a coaching call, participants make their donation of choice and schedule their session, experiencing the transformative power of coaching while supporting meaningful causes.

For more information about Coaching for Causes and to view the list of participating coaches and causes, visit https://www.coachingforcauses.com/

Media Contact
Company Name: Coaching for Causes
Contact Person: Chan Desai
Email: Send Email
Phone: 8136786828
Country: United States
Website: https://www.coachingforcauses.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Coaching for Causes: Empowering personal growth while giving back

Uveitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2024-2034), Investigates DelveInsight | Tarsier Pharma, Roche, Eli Lilly and Company, Oculis, Acelyrin/ Affibody Medical

The Uveitis Market size was valued approximately USD 1,544 Million in 2023 and the report offers an in-depth understanding of the Uveitis, historical and forecasted epidemiology as well as the Uveitis market trends in the 7MM.

DelveInsight’s “Uveitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Uveitis, historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Uveitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Uveitis Market Forecast

 

Some of the key facts of the Uveitis Market Report: 

  • The Uveitis market size was valued approximately USD 1,544 Million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In 2023, the United States held the largest market share for uveitis, with a value of approximately USD 813.44 million, surpassing the combined market sizes of the EU4 countries (Germany, Italy, France, and Spain), the UK, and Japan.

  • Within the EU4 and the UK, Germany boasted the highest market size, reaching around USD 118.28 million in 2023. Projections suggest this figure will rise further, with Germany anticipated to lead the market followed by the UK and France by 2034.

  • According to DelveInsight analysis, approximately 1 million diagnosed prevalent cases of uveitis were identified in the 7MM in 2023. This figure is anticipated to rise over the study period from 2020 to 2034.

  • Based on DelveInsight’s analysis, the United States contributed the largest share, approximately 38%, of the total diagnosed prevalent cases of uveitis in the 7MM in 2023. It is projected that these cases will continue to rise by 2034.

  • In the United States, it was estimated that in 2023 there were around 34,351 cases of infectious uveitis and noninfectious uveitis, respectively. These figures are anticipated to undergo changes during the forecast period from 2024 to 2034.

  • In 2023, Japan reported roughly 214,000 diagnosed prevalent cases of uveitis. According to DelveInsight’s analysis, these diagnosed prevalent cases are projected to decline by 2034.

  • Key Uveitis Companies: Tarsier Pharma, Oculis Pharma, Roche/Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin/Affibody Medical, Priovant Therapeutics (Roivant Sciences and Pfizer), Clearside Biomedical, Inc., Eli Lilly and Company, ACELYRIN Inc., AbbVie, National Eye Institute, AbbVie, Massachusetts Eye Research, Priovant Therapeutics, Inc., Alumis Inc, Quan Dong Nguyen, Soligenix, Ganzhou Hemay Pharmaceutical, Amgen, and others

  • Key Uveitis Therapies: TRS01, Licaminlimab (OCS-02), Vamikibart (RO720220/RG6179), OLUMIANT (baricitinib), EYS606, Izokibep, Brepocitinib, QLETLI, Bio-Thera Solutios, triamcinolone acetonide (Triesence®), Baricitinib, Izokibep, Adalimumab, B27PD, adalimumab, Ixekizumab Prefilled Syringe, Brepocitinib, ESK-001, OCS-01, Dusquetide, Hemay005, Apremilast, and others

  • The Uveitis epidemiology based on gender analyzed that noninfectious uveitis cases are higher in number than infectious uveitis cases

  • The Uveitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Uveitis pipeline products will significantly revolutionize the Uveitis market dynamics.

 

Uveitis Overview

Uveitis is a condition characterized by inflammation of the uvea, which is the middle layer of the eye. The uvea consists of the iris, ciliary body, and choroid, and inflammation can affect one or more of these structures. Uveitis can be acute or chronic and may involve one or both eyes.

 

Get a Free sample for the Uveitis Market Report:

https://www.delveinsight.com/report-store/uveitis-market

 

Uveitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Uveitis Epidemiology Segmentation:

The Uveitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Uveitis

  • Prevalent Cases of Uveitis by severity

  • Gender-specific Prevalence of Uveitis

  • Diagnosed Cases of Episodic and Chronic Uveitis

 

Download the report to understand which factors are driving Uveitis epidemiology trends @ Uveitis Epidemiology Forecast

 

Uveitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Uveitis market or expected to get launched during the study period. The analysis covers Uveitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Uveitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Uveitis Therapies and Key Companies

  • TRS01: Tarsier Pharma

  • Licaminlimab (OCS-02): Oculis Pharma

  • Vamikibart (RO720220/RG6179): Roche/Eleven Biotherapeutics

  • OLUMIANT (baricitinib): Eli Lilly and Company

  • EYS606: Eyevensys

  • Izokibep: Acelyrin/Affibody Medical

  • Brepocitinib: Priovant Therapeutics (Roivant Sciences and Pfizer)

  • QLETLI: Bio-Thera Solutions

  • triamcinolone acetonide (Triesence®): Clearside Biomedical, Inc.

  • Baricitinib: Eli Lilly and Company

  • Izokibep: ACELYRIN Inc.

  • Adalimumab: AbbVie

  • B27PD: National Eye Institute

  • adalimumab: AbbVie

  • Ixekizumab Prefilled Syringe: Massachusetts Eye Research

  • Brepocitinib: Priovant Therapeutics, Inc.

  • ESK-001: Alumis Inc

  • OCS-01: Quan Dong Nguyen

  • Dusquetide: Soligenix

  • Hemay005: Ganzhou Hemay Pharmaceutical

  • Apremilast: Amgen

 

Discover more about therapies set to grab major Uveitis market share @ Uveitis Treatment Market

 

Uveitis Market Strengths

  • The remarkable advances in ocular immunology over the past decades have led to a better understanding of the molecular mechanisms that underlie etiology and susceptibility to uveitis

  • New drugs with diverse mechanisms of action and routes of administration have been approved in the recent past, improving the treatment regime

 

Uveitis Market Opportunities

  • Opportunity for companies to implement knowledge from recent advances in understanding the etiologies associated with uveitis to evaluate potential drugs with novel targets 

  • Biomarker discovery and proteomics provide potential targets for therapeutic intervention by the drugs that are available and accessible, besides providing information about the drug that can be avoided

 

Scope of the Uveitis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Uveitis Companies: Tarsier Pharma, Oculis Pharma, Roche/Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin/Affibody Medical, Priovant Therapeutics (Roivant Sciences and Pfizer), Clearside Biomedical, Inc., Eli Lilly and Company, ACELYRIN Inc., AbbVie, National Eye Institute, AbbVie, Massachusetts Eye Research, Priovant Therapeutics, Inc., Alumis Inc, Quan Dong Nguyen, Soligenix, Ganzhou Hemay Pharmaceutical, Amgen, and others

  • Key Uveitis Therapies: TRS01, Licaminlimab (OCS-02), Vamikibart (RO720220/RG6179), OLUMIANT (baricitinib), EYS606, Izokibep, Brepocitinib, QLETLI, Bio-Thera Solutios, triamcinolone acetonide (Triesence®), Baricitinib, Izokibep, Adalimumab, B27PD, adalimumab, Ixekizumab Prefilled Syringe, Brepocitinib, ESK-001, OCS-01, Dusquetide, Hemay005, Apremilast, and others

  • Uveitis Therapeutic Assessment: Uveitis current marketed and Uveitis emerging therapies

  • Uveitis Market Dynamics: Uveitis market drivers and Uveitis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Uveitis Unmet Needs, KOL’s views, Analyst’s views, Uveitis Market Access and Reimbursement 

 

To know more about Uveitis companies working in the treatment market, visit @ Uveitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Uveitis Market Report Introduction

2. Executive Summary for Uveitis

3. SWOT analysis of Uveitis

4. Uveitis Patient Share (%) Overview at a Glance

5. Uveitis Market Overview at a Glance

6. Uveitis Disease Background and Overview

7. Uveitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Uveitis 

9. Uveitis Current Treatment and Medical Practices

10. Uveitis Unmet Needs

11. Uveitis Emerging Therapies

12. Uveitis Market Outlook

13. Country-Wise Uveitis Market Analysis (2020–2034)

14. Uveitis Market Access and Reimbursement of Therapies

15. Uveitis Market Drivers

16. Uveitis Market Barriers

17.  Uveitis Appendix

18. Uveitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Uveitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2024-2034), Investigates DelveInsight | Tarsier Pharma, Roche, Eli Lilly and Company, Oculis, Acelyrin/ Affibody Medical

Dry Age-related Macular Degeneration Market to Observe Impressive Growth During the Forecast Period (2024-2034), Evaluates DelveInsight | Apellis Pharma, Iveric bio., Allegro Ophthalmics, NGM Biopharm

The Dry Age-related Macular Degeneration Market size was valued at USD 1.3 billion in the year 2022 and the report offersan in-depth understanding of the Dry Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Dry Age-related Macular Degeneration market trends in the 7MM.

The Dry Age-related Macular Degeneration market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Age-related Macular Degeneration pipeline products will significantly revolutionize the Dry Age-related Macular Degeneration market dynamics.  

 

DelveInsight’s “Dry Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034″ report offersan in-depth understanding of the Dry Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Dry Age-related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Dry Age-related Macular Degeneration market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Dry Age-related Macular Degeneration market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dry Age-related Macular Degeneration Market Insights

 

Some of the key facts of the Dry Age-related Macular Degeneration Market Report: 

  • The Dry Age-related Macular Degeneration market size was valued at USD 1.3 billion in the year 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034) 

  • In January 2024, Tilak Healthcare, a digital health company based in France, revealed promising outcomes from a clinical study evaluating a mobile application designed to enable individuals with chronic macular degeneration to track their vision. Known as TIL002, this multicenter trial conducted across three French hospitals showcased that the OdySight app, which holds a CE mark, exhibited strong agreement with conventional methods used to assess vision deterioration.

  • In December 2023, Laboratoires Théa acquired two promising antisense oligonucleotide (AON) therapies for inherited retinal diseases from ProQR Therapeutics. 

  • In August 2023, MeiraGTx reported the completion of enrollment for the Phase III LUMEOS clinical trial for botaretigene sparoparvovec, intended for the treatment of X-linked retinitis pigmentosa (XLRP).

  • In 2023, there were approximately 274,000 prevalent cases of retinitis pigmentosa in the 7MM, and it is anticipated that this number will rise during the projected period.

  • In the 7MM, nonsyndromic retinitis pigmentosa is more common than syndromic retinitis pigmentosa, with approximately 187,000 cases reported in 2023.

  • In 2023, autosomal dominant retinitis pigmentosa stood out as the most prevalent form among common types of retinitis pigmentosa in the United States, with approximately 22,000 reported cases. This includes autosomal recessive retinitis pigmentosa, X-linked retinitis pigmentosa, sporadic/simplex cases, and Leber congenital amaurosis (LCA).

  • Information from multiple sources including the American Macular Degeneration Foundation (2022), Prevent Blindness (2022), Fort Lauderdale Eye Institute (2022), among others, was analyzed. The review indicated that approximately 85–90% of macular degeneration cases are classified as the “dry” (atrophic) type.

  • In 2022, there were an estimated 11 million diagnosed cases of dry age-related macular degeneration (AMD) in the United States.

  • Additional findings indicate that individuals diagnosed with early or intermediate age-related macular degeneration (AMD) make up around 85–90% of all AMD cases, and approximately 10–15% of these patients eventually progress to the wet form of the disease. Geographic atrophy (GA) accounts for half of the exudative form of AMD.

  • In the United States in 2022, there were approximately 10 million diagnosed cases of dry age-related macular degeneration (AMD) classified as early or intermediate stages, and 1 million cases categorized as advanced dry AMD, specifically geographic atrophy associated with dry AMD.

  • Key Dry Age-related Macular Degeneration Companies: Apellis Pharmaceuticals, Iveric bio., Belite Bio, Novartis, CellCure Neurosciences, Allegro Ophthalmics, Stealth BioTherapeutics Inc., Luxa Biotechnology, LLC, Smilebiotek Zhuhai Limited, Gyroscope Therapeutics Limited, Hoffmann-La Roche, Allegro Ophthalmics, LLC, Astellas Institute for Regenerative, Sucampo Pharma Americas, LLC, Novartis, University of California, San Francisco, StemCells, Inc., Acuity Medical International, Sirion Therapeutics, Inc., IVERIC bio, Inc., Kubota Vision Inc., Eyestem Research Pvt. Ltd., Gyroscope Therapeutics, and others 

  • Key Dry Age-related Macular Degeneration Therapies: Pegcetacoplan, Zimura, Tinlarebant, PPY988/GT005, OpRegen, Luminate, Elamipretide, RPESC-RPE-4W, QA102/Placebo, GT005, OpRegen, Risuteganib, MA09-hRPE, unoprostone isopropyl, Iptacopan (LNP023), Metformin, HuCNS-SC cells, Tesmac, Fenretinide, Zimura, ACU-4429, Eyecyte-RPE™, GT005, and others

  • The Dry Age-related Macular Degeneration market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Age-related Macular Degeneration pipeline products will significantly revolutionize the Dry Age-related Macular Degeneration market dynamics.

 

Dry Age-related Macular Degeneration Overview

Dry age-related macular degeneration (AMD) is a common eye condition that affects the macula, a small area near the center of the retina responsible for sharp, central vision. In dry AMD, the cells of the macula gradually break down, leading to a gradual loss of central vision over time.

 

Get a Free sample for the Dry Age-related Macular Degeneration Market Report:

https://www.delveinsight.com/report-store/dry-age-macular-degeneration-market

 

Dry Age-related Macular Degeneration Market  

The dynamics of the Dry Age-related Macular Degeneration market are anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2020-2034. 

 

Dry Age-related Macular Degeneration Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Dry Age-related Macular Degeneration Epidemiology Segmentation:

The Dry Age-related Macular Degeneration market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Dry Age-related Macular Degeneration

  • Prevalent Cases of Dry Age-related Macular Degeneration by severity

  • Gender-specific Prevalence of Dry Age-related Macular Degeneration

  • Diagnosed Cases of Episodic and Chronic Dry Age-related Macular Degeneration

 

Download the report to understand which factors are driving Dry Age-related Macular Degeneration epidemiology trends @ Dry Age-related Macular Degeneration Epidemiological Insights

 

Dry Age-related Macular Degeneration Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dry Age-related Macular Degeneration market or expected to get launched during the study period. The analysis covers Dry Age-related Macular Degeneration market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dry Age-related Macular Degeneration Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Dry Age-related Macular Degeneration Therapies and Key Companies

  • Pegcetacoplan: Apellis Pharmaceuticals

  • Zimura: Iveric bio. 

  • Tinlarebant: Belite Bio

  • PPY988/GT005: Novartis

  • OpRegen: CellCure Neurosciences

  • Luminate: Allegro Ophthalmics

  • Elamipretide: Stealth BioTherapeutics Inc.

  • RPESC-RPE-4W: Luxa Biotechnology, LLC

  • QA102/Placebo: Smilebiotek Zhuhai Limited

  • GT005: Gyroscope Therapeutics Limited

  • OpRegen: Hoffmann-La Roche

  • Risuteganib: Allegro Ophthalmics, LLC

  • MA09-hRPE: Astellas Institute for Regenerative

  • unoprostone isopropyl: Sucampo Pharma Americas, LLC

  • Iptacopan (LNP023): Novartis

  • Metformin: University of California, San Francisco

  • HuCNS-SC cells: StemCells, Inc.

  • Tesmac: Acuity Medical International

  • Fenretinide: Sirion Therapeutics, Inc.

  • Zimura: IVERIC bio, Inc.

  • ACU-4429: Kubota Vision Inc.

  • Eyecyte-RPE™: Eyestem Research Pvt. Ltd.

  • GT005: Gyroscope Therapeutics

 

To know more about Dry Age-related Macular Degeneration treatment, visit @ Dry Age-related Macular Degeneration Medications

 

Dry Age-related Macular Degeneration Market Strengths

  • • AAVs have emerged as the predominant vectors for delivering genes of interest to target tissues with improved specificity, efficiency, and safety in the case of retinitis pigmentosa. 

  • Gene therapy is advancing by leaps and bounds as it is more effective, less invasive, and relatively safer in the short term than retinal transplantation.

 

Dry Age-related Macular Degeneration Market Opportunities

  • Alongside advances in cell and gene technologies, research advances in the fields of optogenetics and electronic retinal prostheses also represent encouraging progress for the treatment of retinitis pigmentosa and other inherited retinal dystrophies. 

  • Cell therapies such as jCell by jCyte, once approved, will likely have a broad application as they are mutation-independent. Treatment can be initiated earlier as cell therapies do not require genetic testing.

 

Scope of the Dry Age-related Macular Degeneration Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Dry Age-related Macular Degeneration Companies: Apellis Pharmaceuticals, Iveric bio., Belite Bio, Novartis, CellCure Neurosciences, Allegro Ophthalmics, Stealth BioTherapeutics Inc., Luxa Biotechnology, LLC, Smilebiotek Zhuhai Limited, Gyroscope Therapeutics Limited, Hoffmann-La Roche, Allegro Ophthalmics, LLC, Astellas Institute for Regenerative, Sucampo Pharma Americas, LLC, Novartis, University of California, San Francisco, StemCells, Inc., Acuity Medical International, Sirion Therapeutics, Inc., IVERIC bio, Inc., Kubota Vision Inc., Eyestem Research Pvt. Ltd., Gyroscope Therapeutics, and others

  • Key Dry Age-related Macular Degeneration Therapies: Pegcetacoplan, Zimura, Tinlarebant, PPY988/GT005, OpRegen, Luminate, Elamipretide, RPESC-RPE-4W, QA102/Placebo, GT005, OpRegen, Risuteganib, MA09-hRPE, unoprostone isopropyl, Iptacopan (LNP023), Metformin, HuCNS-SC cells, Tesmac, Fenretinide, Zimura, ACU-4429, Eyecyte-RPE™, GT005, and others

  • Dry Age-related Macular Degeneration Therapeutic Assessment: Dry Age-related Macular Degeneration current marketed and Dry Age-related Macular Degeneration emerging therapies

  • Dry Age-related Macular Degeneration Market Dynamics: Dry Age-related Macular Degeneration market drivers and Dry Age-related Macular Degeneration market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Dry Age-related Macular Degeneration Unmet Needs, KOL’s views, Analyst’s views, Dry Age-related Macular Degeneration Market Access and Reimbursement 

 

Discover more about therapies set to grab major Dry Age-related Macular Degeneration market share @ Dry Age-related Macular Degeneration market forecast

 

Table of Contents 

1. Dry Age-related Macular Degeneration Market Report Introduction

2. Executive Summary for Dry Age-related Macular Degeneration

3. SWOT analysis of Dry Age-related Macular Degeneration

4. Dry Age-related Macular Degeneration Patient Share (%) Overview at a Glance

5. Dry Age-related Macular Degeneration Market Overview at a Glance

6. Dry Age-related Macular Degeneration Disease Background and Overview

7. Dry Age-related Macular Degeneration Epidemiology and Patient Population

8. Country-Specific Patient Population of Dry Age-related Macular Degeneration 

9. Dry Age-related Macular Degeneration Current Treatment and Medical Practices

10. Dry Age-related Macular Degeneration Unmet Needs

11. Dry Age-related Macular Degeneration Emerging Therapies

12. Dry Age-related Macular Degeneration Market Outlook

13. Country-Wise Dry Age-related Macular Degeneration Market Analysis (2020–2034)

14. Dry Age-related Macular Degeneration Market Access and Reimbursement of Therapies

15. Dry Age-related Macular Degeneration Market Drivers

16. Dry Age-related Macular Degeneration Market Barriers

17.  Dry Age-related Macular Degeneration Appendix

18. Dry Age-related Macular Degeneration Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dry Age-related Macular Degeneration Market to Observe Impressive Growth During the Forecast Period (2024-2034), Evaluates DelveInsight | Apellis Pharma, Iveric bio., Allegro Ophthalmics, NGM Biopharm

Retinitis Pigmentosa Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2024-2034), States DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics

The Retinitis Pigmentosa Market size was valued at USD 392.42 Million in the year 2020 and the report offers an in-depth understanding of the Retinitis Pigmentosa, historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the 7MM.

The Retinitis Pigmentosa market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Retinitis Pigmentosa pipeline products will significantly revolutionize the Retinitis Pigmentosa market dynamics.  

 

DelveInsight’s “Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Retinitis Pigmentosa, historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Retinitis Pigmentosa market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Retinitis Pigmentosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Retinitis Pigmentosa Market Insights

 

Some of the key facts of the Retinitis Pigmentosa Market Report: 

  • The Retinitis Pigmentosa market size was valued at USD 392.42 Million in the year 2020 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In December 2023, Laboratoires Théa obtained two developing antisense oligonucleotide (AON) therapies targeting inherited retinal disorders from ProQR Therapeutics.

  • In August 2023, MeiraGTx disclosed the completion of enrollment for the Phase III LUMEOS clinical trial evaluating botaretigene sparoparvovec as a treatment for X-linked retinitis pigmentosa (XLRP).

  • In 2023, there were approximately 274,000 prevalent cases of retinitis pigmentosa across the 7MM, and this number is projected to rise in the forecast period.

  • In the 7MM, nonsyndromic retinitis pigmentosa is more common than syndromic retinitis pigmentosa, with approximately 187,000 cases reported in 2023.

  • Key Retinitis Pigmentosa Companies: SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc, Coave Therapeutics, jCyte, Nightstar Therapeutics, ReNeuron, and others

  • Key Retinitis Pigmentosa Therapies: CTx-PDE6b, jCell, AAV8-RPGR, BIIB112, Human retinal progenitor cells (hrpc) cell, and others

  • The Retinitis Pigmentosa epidemiology based on gender analyzed that a higher percentage of diagnosed prevalence was observed for males, in comparison to females, except Japan, where females occupy a larger patient pool than males

 

Retinitis Pigmentosa Overview

Retinitis pigmentosa (RP) is a group of inherited eye disorders characterized by the breakdown and loss of cells in the retina, the light-sensitive tissue lining the back of the eye. This condition causes gradual vision loss, typically starting with difficulty seeing at night or in low light, followed by a narrowing of the visual field (tunnel vision) and eventual loss of central vision.

 

Get a Free sample for the Retinitis Pigmentosa Market Report:

https://www.delveinsight.com/report-store/retinitis-pigmentosa-market

 

Retinitis Pigmentosa Market  

The dynamics of the Retinitis Pigmentosa market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.  

Retinitis Pigmentosa Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Retinitis Pigmentosa Epidemiology Segmentation:

The Retinitis Pigmentosa market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Retinitis Pigmentosa

  • Prevalent Cases of Retinitis Pigmentosa by severity

  • Gender-specific Prevalence of Retinitis Pigmentosa

  • Diagnosed Cases of Episodic and Chronic Retinitis Pigmentosa

 

Download the report to understand which factors are driving Retinitis Pigmentosa epidemiology trends @ Retinitis Pigmentosa Epidemiological Insights

 

Retinitis Pigmentosa Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Retinitis Pigmentosa market or expected to get launched during the study period. The analysis covers Retinitis Pigmentosa market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Retinitis Pigmentosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Retinitis Pigmentosa Therapies and Key Companies

  • EA-2353: Endogena Therapeutics, Inc

  • OCU400-301: Ocugen

  • BS01: Bionic Sight LLC

  • CPK850: Novartis

  • AAV2/5-hPDE6B: eyeDNA Therapeutics

  • hRPC: ReNeuron Limited

  • SPVN06: SparingVision

  • RST-001: AbbVie

  • KIO-301: Kiora Pharmaceuticals

  • OCU400: Ocugen

  • QR-1123: ProQR Therapeutics

  • Ultevursen: ProQR Therapeutics

 

To know more about Retinitis Pigmentosa treatment, visit @ Retinitis Pigmentosa Medications

 

Retinitis Pigmentosa Market Strengths

  • AAVs have emerged as the predominant vectors for delivering genes of interest to target tissues with improved specificity, efficiency, and safety in the case of retinitis pigmentosa. 

  • Gene therapy is advancing by leaps and bounds as it is more effective, less invasive, and relatively safer in the short term than retinal transplantation.

 

Retinitis Pigmentosa Market Opportunities

  • Alongside advances in cell and gene technologies, research advances in the fields of optogenetics and electronic retinal prostheses also represent encouraging progress for the treatment of retinitis pigmentosa and other inherited retinal dystrophies. 

  • Cell therapies such as jCell by jCyte, once approved, will likely have a broad application as they are mutation-independent. Treatment can be initiated earlier as cell therapies do not require genetic testing.

 

Scope of the Retinitis Pigmentosa Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Retinitis Pigmentosa Companies: SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc, Coave Therapeutics, jCyte, Nightstar Therapeutics, ReNeuron, and others

  • Key Retinitis Pigmentosa Therapies: CTx-PDE6b, jCell, AAV8-RPGR, BIIB112, Human retinal progenitor cells (hrpc) cell, and others

  • Retinitis Pigmentosa Therapeutic Assessment: Retinitis Pigmentosa current marketed and Retinitis Pigmentosa emerging therapies

  • Retinitis Pigmentosa Market Dynamics: Retinitis Pigmentosa market drivers and Retinitis Pigmentosa market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Retinitis Pigmentosa Unmet Needs, KOL’s views, Analyst’s views, Retinitis Pigmentosa Market Access and Reimbursement 

 

Discover more about therapies set to grab major Retinitis Pigmentosa market share @ Retinitis Pigmentosa market forecast

 

Table of Contents 

1. Retinitis Pigmentosa Market Report Introduction

2. Executive Summary for Retinitis Pigmentosa

3. SWOT analysis of Retinitis Pigmentosa

4. Retinitis Pigmentosa Patient Share (%) Overview at a Glance

5. Retinitis Pigmentosa Market Overview at a Glance

6. Retinitis Pigmentosa Disease Background and Overview

7. Retinitis Pigmentosa Epidemiology and Patient Population

8. Country-Specific Patient Population of Retinitis Pigmentosa 

9. Retinitis Pigmentosa Current Treatment and Medical Practices

10. Retinitis Pigmentosa Unmet Needs

11. Retinitis Pigmentosa Emerging Therapies

12. Retinitis Pigmentosa Market Outlook

13. Country-Wise Retinitis Pigmentosa Market Analysis (2020–2034)

14. Retinitis Pigmentosa Market Access and Reimbursement of Therapies

15. Retinitis Pigmentosa Market Drivers

16. Retinitis Pigmentosa Market Barriers

17.  Retinitis Pigmentosa Appendix

18. Retinitis Pigmentosa Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Retinitis Pigmentosa Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2024-2034), States DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics

Schneider Electric highlights the importance of software, automation and electrification in accelerating industrial competitiveness

• Schneider Electric outlines how software-defined automation is driving industrial growth at Hannover Messe

• Alongside AVEVA, company unveils latest innovations aimed at boosting industrial productivity, resilience, and efficiency

• Showcasing the importance of deep domain expertise, it will demonstrate how its solutions support the entire industrial ecosystem at its #HM24 booth (Hall 11, Stand C52)

Schneider Electric, the industrial technology leader of energy management and automation, will showcase the latest innovations in its portfolio, including industrial software, Artificial Intelligence and Digital Twin technology. These solutions will be demonstrated through the lens of a digital and sustainable life science campus, highlighting Schneider’s deep domain expertise across the entire industrial value chain.

“With industry contributing around 45% of global greenhouse gas emissions[1], it is clear we must act to reduce this and support industrial decarbonization as quickly as possible. The question is how we achieve this while boosting productivity,” said Barbara Frei, Executive Vice President, Industrial Automation at Schneider Electric. “Automation, which is at the heart of industrial operational technology optimizes production processes and is a key enabler for successful digital transformation. It drives productivity and efficiency and helps make the most of energy and raw materials.”

Driving productivity and efficiency through Software-Defined Automation

Hannover Messe, the world’s premier industrial trade fair, is taking place in Hannover, Germany, from April 22 to 26. At the event, Schneider Electric is presenting its vision for automation.

Following the launch of EcoStruxure Automation Expert in 2020, the company continues to build upon its pioneering open, software-defined approach to automation, developing a single, scalable industrial automation environment for continuous, hybrid or discrete processes.

Focusing on supporting customers’ need to be agile and innovative in response to industrial challenges while simultaneously protecting investments, the company aims to reduce total cost of ownership, simplify processes and operations, and enable industry to operate at higher levels of efficiency and resiliency.

Frei continued “Much of the automation in operation today was designed and installed decades ago, based upon hardware tied to a single supplier and before the massive computing power we have now. With software defined automation and our open approach, we simplify the existing complexity and allow customers to update or change their automation based on what they need, when they need it and from whom they want it.”

New industrial innovations showcased at Schneider Electric’s booth (Hall 11, Booth C52)

  • CONNECT: This agnostic, end-to-end industrial intelligence platform from AVEVA enables visibility and integration of engineering and operational data across the entire value chain, building an ecosystem of employees, partners and even customers. Enriched with AI and founded on the intelligent digital twin, CONNECT empowers businesses to unlock efficiencies and drive sustainability using Schneider Electric, AVEVA, etap, RIB and other third-party software providers.
  • EcoStruxure Plant Apps: EcoStuxure Plant Predictive Energy the latest of Schneider’s Industrial IoT software solutions, running on CONNECT Data Services, monitors energy consumption anomalies across multiple sites to enable better decision-making and significant energy savings.
  • EcoStruxure Edge Apps: an open, scalable, and ready-to-use ecosystem that leverages edge compute and AI technology, provides real-time data processing by converting data into actionable insights at the source – machine, line, or plant-floor level. The first Apps to be launched and demonstrated at HM include EcoStruxure Edge Apps Manager, Condition-Based Maintenance, and Autonomous Yield Optimization.
  • Hybrid Cloud MES: AVEVA’s MES takes a new dimension with applications adopting CONNECT and gaining new capabilities: Data management, Visualization, and Advanced analytics.
  • EvoPacT™ HVX: a new circuit breaker for medium-voltage power distribution with an operational lifespan up to three-times longer than today’s circuit breakers. With comprehensive health monitoring and IoT-enabled features, it helps users and partners make a sustainability impact and meet the needs of an all-digital, all-electric world.
  • MasterPacT MTZ Active: the latest addition to this comprehensive range of high-power air circuit breakers leverages the advanced digital features of its MicroLogic X control unit for maximum maintenance and energy efficiencies.
  • Lexium SCARA Robot: A new ultra-compact, high-speed industrial robot with high positioning accuracies for improving productivity and efficiency in manufacturing and assembly processes. It seamlessly integrates into unified machine control systems, enabling centralized control of multiple robots to foster synchronization and provide collaborative data flows, addressing the demands of smarter, more flexible, and sustainable manufacturing.
  • Automation application copilot: Leveraging the power of Gen AI to boost engineering productivity, this application offers a highly assisted user experience to a control engineer for total application generation workflow tasks including application structure, asset creation from associated libraries and code/documentation/test case generation.
  • TeSys motor control: celebrating 100 years of innovation, Schneider Electric‘s world-leading reliable, sustainable, and efficient motor control solutions are connected, integrated and IoT-ready to provide industry 4.0 protection.

Schneider Electric in the wider industrial ecosystem: Co-created innovations

  • Automation application copilot for PLC code generation [Microsoft Booth, Hall 17, booth G06]: Designed to help engineers to rapidly write high-quality, tested, and validated code for Programmable Logic controllers (PLCs), this code generation solution combines Schneider’s deep industrial domain expertise with Microsoft’s cutting-edge Generative AI technology. The tool is changing the status quo by automating repetitive tasks and providing intelligent code suggestions to reduce programming time.
  • MARGO Initiative under Linux Foundation launch [Capgemini Booth, Hall 15, booth F52]: Schneider Electric and AVEVA cement their founding membership of MARGO on Tuesday April 23 at 11.00 CET. This new open standard initiative for industrial automation edge interoperability aims to accelerate digital transformation and foster increased growth for organizations of all sizes. Hosted by the Joint Development Foundation, as part of the Linux Foundation, this initiative aligns with Schneider’s Open Automation approach.
  • Data4industry-X [Platform 4.0 booth]: Trusted data is fundamental to driving collaboration and establishing new industrial models that accelerate transformation. Schneider Electric is part of the Data4Industry-X, a Gaia-X Lighthouse project and part of Manufacturing-X initiative, supported by the France 2030 national investment plan and the NextGenerationEU economic recovery program. Data4Industry-X relies on technological and industrial expertise to support industrial digital transformation and capitalize on the high potential of industrial data. 

Press Activities: Schneider Electric sessions for media include:

Monday, April 22, 13:00 – 14.00 CET – Press & Analyst conference – Schneider Electric stand (Hall 11, booth C52) in the learning lounge: hear what makes an industrial technology leader, including Schneider Electric’s vision of software-defined automation and the latest innovations from AVEVA. Followed by a booth tour from 14.15 – 14.45 to see the solutions in action.

Tuesday, April 23, 10:00 – 11.00 CET – Press & Analyst breakfast – Schneider Electric stand (Hall 11, booth C52) in the booth hospitality area: join senior executives to deep dive into the latest offerings including industrial applications on the edge, AVEVA’s Hybrid Manufacturing Execution System and AI in industrial applications. Followed by a booth tour from 11.15 – 11.45.

Schneider Electric In-Stand activities (Hall 11, Booth C52):

  • Innovation talks: experts and representatives from leading industrial companies discuss the latest trends and technologies that are impacting industrial markets.
  • Guided tours and interactive sessions: join customers and subject matter experts to see how Schneider Electric is supporting industrial operations across every step of the value chain.
  • Schneider Electric solutions in action: including EcoStruxure Automation Expert, Industrial Digital Transformation Services, CONNECT, Machine Digital Twin and AVEVA Unified Operations Center.
  • Green and digital roadshow truck: located between hall 11 and hall 9

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric highlights the importance of software, automation and electrification in accelerating industrial competitiveness

As AI boom triggers data centre growth, Schneider Electric steps up to seize the opportunity

Use of artificial intelligence has created the need for enhanced data processing capabilities, and this is leading to a surge in demand for cooling solutions, says Pankaj Sharma, EVP, Secure Power Division & Data Center Business, Schneider Electric.

The rapid growth of artificial intelligence (AI) has skyrocketed the demand for data processing, resulting in an increased need for cooling solutions. Keeping this in view, Schneider Electric recently inaugurated a factory in Bangalore that will focus on developing innovative cooling solutions to meet the growing exponential demand for the data centre ecosystem. The company specifies that the products and solutions would be used for data centres, telecom, commercial and industrial applications in domestic and international markets — 85% of the products manufactured here will be exported. The primary focus would be to make systems that provide targeted cooling directly at the heat source, maximising server performance but minimising energy consumption.

In an interaction with ET Online, Pankaj Sharma, EVP, Secure Power Division & Data Center Business, Schneider Electric, says the data centre sector in India is witnessing remarkable expansion, fuelled by the rise of cloud computing, artificial intelligence, and other data-centric applications. This has served as inspiration for the French multinational to expand its operations with a continued focus on expanding India’s data centre ecosystem besides catering to global demand. 

Could you elaborate on the innovative strategies being implemented by Schneider Electric to minimise the environmental impact of energy-intensive data centres globally?Pankaj Sharma: The demand for data centres has been there for almost a decade and it’s growing from a global perspective, including India. In fact, it’s even faster in India. There has been a transition from enterprise data centres to cloud data centres, e-commerce, blockchain and metaverse and now AI. With that entire demand and now with AI, the demand for data centres has gone up even more. A global agency on energy consumption, the IEA, talks about how the power consumption at data centres is about 2% at the global level, and is predicted to go to almost 6%. So that’s the level of increase we are expecting.

Now, from a sustainability point of view, even before AI became the buzzword, we’ve always had innovative solutions. We do medium voltage, low voltage, the entire power distribution terrain, etc. We have very simple, but innovative technologies that focus on sustainability. An example would be our UPS systems and the grid compatibility which some of these systems have, which helps in sustainability. In terms of medium voltage switchgear, Schneider Electric uses air instead of gases, which is very important for pushing sustainability. Our EcoCare programme plays a significant role in promoting sustainability by managing heat generation at the rack level in data centres and other critical infrastructure. The programme focuses on optimising the lifecycle management of core technologies in modular data centres, including components like low voltage switchgear, UPS and cooling systems. By employing condition-based maintenance, the programme ensures that equipment operates efficiently, thus reducing unnecessary heat generation and energy use.We have also introduced numerous innovations around liquid cooling systems, which we aim to produce in this Bangalore facility. Through such measures, we look at solving the sustainability problem.

About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On. Our mission is to be your digital partner for Sustainability and Efficiency. We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: As AI boom triggers data centre growth, Schneider Electric steps up to seize the opportunity

Under The Bonnet, Schneider Electric Infrastructure’s (NSE:SCHNEIDER) Returns Look Impressive

What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. Ultimately, this demonstrates that it’s a business that is reinvesting profits at increasing rates of return. Speaking of which, we noticed some great changes in Schneider Electric Infrastructure’s (NSE:SCHNEIDER) returns on capital, so let’s have a look.

What Is Return On Capital Employed (ROCE)?

For those that aren’t sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. To calculate this metric for Schneider Electric Infrastructure, this is the formula:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets – Current Liabilities)

0.40 = ₹2.7b ÷ (₹14b – ₹7.3b) (Based on the trailing twelve months to December 2023).

Thus, Schneider Electric Infrastructure has an ROCE of 40%. That’s a fantastic return and not only that, it outpaces the average of 18% earned by companies in a similar industry.

Historical performance is a great place to start when researching a stock so above you can see the gauge for Schneider Electric Infrastructure’s ROCE against it’s prior returns. If you want to delve into the historical earnings, check out these free graphs detailing revenue and cash flow performance of Schneider Electric Infrastructure.

The Trend Of ROCE

We like the trends that we’re seeing from Schneider Electric Infrastructure. Over the last five years, returns on capital employed have risen substantially to 40%. Basically the business is earning more per dollar of capital invested and in addition to that, 329% more capital is being employed now too. The increasing returns on a growing amount of capital is common amongst multi-baggers and that’s why we’re impressed.

In another part of our analysis, we noticed that the company’s ratio of current liabilities to total assets decreased to 52%, which broadly means the business is relying less on its suppliers or short-term creditors to fund its operations. Therefore we can rest assured that the growth in ROCE is a result of the business’ fundamental improvements, rather than a cooking class featuring this company’s books. Nevertheless, there are some potential risks the company is bearing with current liabilities that high, so just keep that in mind.

What We Can Learn From Schneider Electric Infrastructure’s ROCE

All in all, it’s terrific to see that Schneider Electric Infrastructure is reaping the rewards from prior investments and is growing its capital base. And a remarkable 632% total return over the last five years tells us that investors are expecting more good things to come in the future. So given the stock has proven it has promising trends, it’s worth researching the company further to see if these trends are likely to persist.

On a final note, we’ve found 1 warning sign for Schneider Electric Infrastructure that we think you should be aware of.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Under The Bonnet, Schneider Electric Infrastructure\’s (NSE:SCHNEIDER) Returns Look Impressive

Schneider Electric launches new storage systems for microgrids

French multinational energy management company Schneider Electric has announced a new Battery Energy Storage System (BESS) for microgrids. It is available in two enclosure sizes and has different storage and discharge configurations.

“Comprised of a battery system, battery management system, power conversion system, and controller, BESS has been tested and validated to work as an integral component of Schneider Electric’s standardized microgrid system, EcoStruxure™ Microgrid Flex,” the company said in a statement. “It is fully integrated into the software suite, which includes EcoStruxure Microgrid Operation and EcoStruxure Microgrid Advisor.”

The BESS 7ft (2.1 m) long enclosure has a power of 60 kW or 90 kW and maximum storage of 246 kWh, with a discharge configuration of two or four hours. It weighs 3.6 metric tons, and it is AC and DC coupled. On the other hand, the BESS 20ft (6.06 m) long enclosure has a power of 250 kW, 375 kW, or 500 kW, and maximum storage of 1,720 kWh, with a discharge configuration of two or four hours. It weighs 25 metric tons, and it is AC coupled only.

“The BESS is a fully self-contained solution built upon a flexible, scalable, and highly-efficient architecture delivering flexibility, helping to minimize energy costs and maximize renewable energy,” the company added. “As part of a microgrid system, the BESS leverages onsite generation sources to optimize the entire system, delivering energy and cost savings while maximizing usage of renewables.”

Both enclosures use Lithium-Ion Iron Phosphate (LFP) batteries, which have a rated calendar life of 15-20 years and more than 6,000 cycles. The BESS’s operating temperature ranges from -20 C to 50 C, and Schneider Electric offers a three-year warranty.

About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On. Our mission is to be your digital partner for Sustainability and Efficiency. We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric launches new storage systems for microgrids

Stargardt Disease Market to Observe Impressive Growth During the Forecast Period (2024-2034), Evaluates DelveInsight | Acucela Inc., Astellas Pharma, Alkeus Pharma

The Stargardt Disease Market Forecast report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the 7MM.

The Stargardt Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.  

 

DelveInsight’s “Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Stargardt Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Stargardt Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Stargardt Disease Market Insights

 

Some of the key facts of the Stargardt Disease Market Report: 

  • The Stargardt Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034) 

  • In January 2024, Alkeus Pharmaceuticals disclosed encouraging interim findings indicating that gildeuretinol effectively arrested the progression of Stargardt disease for a period of up to six years. Within the ongoing TEASE-3 clinical trial targeting early-stage Stargardt disease, the initial three adolescent participants who received oral gildeuretinol acetate remained symptom-free and did not experience any advancement of the disease throughout their treatment duration, which ranged from two years for one patient to six years for two patients.

  • According to information from Orphanet (2023), the prevalence of Stargardt Disease is approximated to vary between 1 in 8,000 to 1 in 10,000 people, with both males and females equally impacted by the condition in Europe.

  • According to the NIH (2023), the projected prevalence of Stargardt macular degeneration stands at approximately 1 in 6,500 individuals within the United States.

  • Key Stargardt Disease Companies: Ocugen, Kubota Vision Inc, Nanoscope Therapeutics Inc., RBP4 Pty Ltd, Stargazer Pharmaceuticals, Inc., Belite Bio, Inc, Alkeus Pharmaceuticals, Inc., IVERIC bio, Inc., Kubota Vision Inc., Astellas Institute, Nanoscope Therapeutics, Alkeus Pharmaceuticals, and others

  • Key Stargardt Disease Therapies: OCU410ST, Emixustat, Gene Therapy-vMCO-010, tinlarebant, STG-001, Tinlarebant, ALK-001, Zimura, Emixustat, MA09-hRPE, MCO-010 (Sonpiretigene Isteparvovec), ALK-001 (Gildeuretinol), and others 

  • The Stargardt Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.

 

Stargardt Disease Overview

Stargardt disease, also known as Stargardt macular dystrophy or juvenile macular degeneration, is a genetic eye disorder that affects the macula, a small area near the center of the retina responsible for sharp, central vision. It is typically diagnosed in childhood or adolescence. Stargardt disease is characterized by the gradual degeneration of the cells in the macula, leading to progressive central vision loss. 

 

Get a Free sample for the Stargardt Disease Market Report:

https://www.delveinsight.com/report-store/stargardt-disease-stgd-market

 

Stargardt Disease Market  

The dynamics of the Stargardt Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.  

“In the near future, there are some positive candidates in the developmental stage by key players such as Acucela Inc (Kubota), Alkeus Pharmaceuticals Inc, Astellas Pharma Inc, Revision Therapeutics and others.” 

 

Stargardt Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Stargardt Disease Epidemiology Segmentation:

The Stargardt Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Stargardt Disease

  • Prevalent Cases of Stargardt Disease by severity

  • Gender-specific Prevalence of Stargardt Disease

  • Diagnosed Cases of Episodic and Chronic Stargardt Disease

 

Download the report to understand which factors are driving Stargardt Disease epidemiology trends @ Stargardt Disease Epidemiological Insights

 

Stargardt Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Stargardt Disease market or expected to get launched during the study period. The analysis covers Stargardt Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Stargardt Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Stargardt Disease Therapies and Key Companies

  • OCU410ST: Ocugen

  • Emixustat: Kubota Vision Inc

  • Gene Therapy-vMCO-010: Nanoscope Therapeutics Inc.

  • tinlarebant: RBP4 Pty Ltd

  • STG-001: Stargazer Pharmaceuticals, Inc.

  • Tinlarebant: Belite Bio, Inc

  • ALK-001: Alkeus Pharmaceuticals, Inc.

  • Zimura: IVERIC bio, Inc.

  • Emixustat: Kubota Vision Inc.

  • MA09-hRPE: Astellas Institute

  • Emixustat : Kubota Pharmaceuticals

  • MCO-010 (Sonpiretigene Isteparvovec): Nanoscope Therapeutics

  • ALK-001 (Gildeuretinol): Alkeus Pharmaceuticals

 

To know more about Stargardt Disease treatment, visit @ Stargardt Disease Medications

 

Stargardt Disease Market Strengths

  • Stargardt Disease has a well-identified genetic basis, primarily associated with mutations in the ABCA4 gene, allowing for targeted research and potential therapeutic interventions.

  • Regulatory agencies, such as the FDA, recognize Stargardt Disease as an orphan disease, providing incentives for the development of orphan drugs and accelerated approval pathways.

 

Stargardt Disease Market Opportunities

  • Ongoing research in gene therapies, pharmacological interventions, and emerging technologies provides opportunities for the development of novel and effective treatments. 

  • Rapid advancements in genetic technologies, including CRISPR-Cas9, offer potential breakthroughs in gene editing and correction of ABCA4 mutations

 

Scope of the Stargardt Disease Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Stargardt Disease Companies: Ocugen, Kubota Vision Inc, Nanoscope Therapeutics Inc., RBP4 Pty Ltd, Stargazer Pharmaceuticals, Inc., Belite Bio, Inc, Alkeus Pharmaceuticals, Inc., IVERIC bio, Inc., Kubota Vision Inc., Astellas Institute, Nanoscope Therapeutics, Alkeus Pharmaceuticals, and others

  • Key Stargardt Disease Therapies: OCU410ST, Emixustat, Gene Therapy-vMCO-010, tinlarebant, STG-001, Tinlarebant, ALK-001, Zimura, Emixustat, MA09-hRPE, MCO-010 (Sonpiretigene Isteparvovec), ALK-001 (Gildeuretinol), Zimura, and others

  • Stargardt Disease Therapeutic Assessment: Stargardt Disease current marketed and Stargardt Disease emerging therapies

  • Stargardt Disease Market Dynamics: Stargardt Disease market drivers and Stargardt Disease market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Stargardt Disease Unmet Needs, KOL’s views, Analyst’s views, Stargardt Disease Market Access and Reimbursement 

 

Discover more about therapies set to grab major Stargardt Disease market share @ Stargardt Disease market forecast

 

Table of Contents 

1. Stargardt Disease Market Report Introduction

2. Executive Summary for Stargardt Disease

3. SWOT analysis of Stargardt Disease

4. Stargardt Disease Patient Share (%) Overview at a Glance

5. Stargardt Disease Market Overview at a Glance

6. Stargardt Disease Disease Background and Overview

7. Stargardt Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Stargardt Disease 

9. Stargardt Disease Current Treatment and Medical Practices

10. Stargardt Disease Unmet Needs

11. Stargardt Disease Emerging Therapies

12. Stargardt Disease Market Outlook

13. Country-Wise Stargardt Disease Market Analysis (2020–2034)

14. Stargardt Disease Market Access and Reimbursement of Therapies

15. Stargardt Disease Market Drivers

16. Stargardt Disease Market Barriers

17.  Stargardt Disease Appendix

18. Stargardt Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Stargardt Disease Market to Observe Impressive Growth During the Forecast Period (2024-2034), Evaluates DelveInsight | Acucela Inc., Astellas Pharma, Alkeus Pharma

Decluttering Boom: INPress International Launches Guide to Help Downsizing Americans Adapt to Post-Pandemic Life

“Young Lady Enjoy Reading “GoodBuy, Things!” and get inspired.”
Explore how Fan Xi Yu’s new guide helps Americans adapt to post-pandemic living by decluttering efficiently. Discover strategies for downsizing homes amid workspace changes and stress from clutter, offering a blueprint for minimalism and well-being.

As working and living environments evolve, decluttering expert Fan Xi Yu is launching a new guide to help Americans streamline their homes for more efficient post-pandemic living.

In “GoodBuy, Things!” (INPress Self-Help Science), Fan addresses the surge in decluttering amid ongoing workspace changes and uncertainty. Recent surveys found 64% of Americans own too many possessions and nearly half experience stress from clutter.

With companies embracing hybrid and remote work models long-term, many workers are reducing personal square footage. Fan’s book helps resize living spaces economically while maintaining quality of life.


Video Link: https://www.youtube.com/embed/7AEPI4aFoSU

“So much excess has accumulated as our lifestyles changed abruptly,” said INPress publisher Sydney Sweet. “Fan’s guidance comes at a critical time of widespread domestic downsizing and renewing focus on what truly sparks joy in life.”

The book coaches strategic decluttering room-by-room and surfaces items donors seek most. Early adopters report raising $1,000 on average from decluttered goods—money better spent on experiences that enrich daily lives rather than deplete storage.


Video Link: https://www.youtube.com/embed/YtJjM1Sw8Fw

As real estate demands shift, “Goodbuy, Things!” creates a blueprint for reducing living costs through minimalism while boosting well-being. With 64% of Americans open to downsizing, the book could reshape post-pandemic living nationwide.

Available wherever books are sold including Amazon, Barnes & Noble, Apple Books and independent retailers, Fan’s guidance arrives as multitudes embrace hybrid schedules requiring optimized domestic functionality. Her method offers keys to post-pandemic domesticity through mindful minimization.

Media Contact
Company Name: INPress International
Contact Person: Sydney Sweet
Email: Send Email
Country: HongKong
Website: https://inpressinternational.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Decluttering Boom: INPress International Launches Guide to Help Downsizing Americans Adapt to Post-Pandemic Life